Jazz Pharmaceuticals stock

JAZZ · NASDAQ · USD

Compare Jazz Pharmaceuticals
$241.55Change from previous close: +0.49%Absolute change: +$1.18

Close · November 13, 2026

Price history

+70.45% over the period

1 year: from $141.71 (November 13, 2025) to $241.55 (November 13, 2026), +70.45%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$241.55
October 30, 2026$215.98
September 30, 2026$231.52
August 31, 2026$250.68
July 31, 2026$252.86
June 30, 2026$240.97
May 29, 2026$236.49
April 30, 2026$203.02
March 31, 2026$189.05
February 27, 2026$190.02
January 30, 2026$164.49
December 31, 2025$170.00
November 28, 2025$176.53
November 13, 2025$141.71

At a glance

  • The company

    Develop and commercialize pharmaceutical products for narcolepsy, epilepsy, cancer, and other diseases

  • Latest results

    Quarter to September 30, 2026 · EPS -$3.88 (estimate $6.30)

TickerLandia's take on Jazz Pharmaceuticals

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$156.95
52-wk high$266.38

−9.32% from the 52-week high

Analysts · 22 analysts

Average target$297.59+23.20% vs. price

Buy 20 · Hold 2 · Sell 0 · Strong buy

TickerLandia Fingerprint: Jazz Pharmaceuticals

Compared with similar companies: very low financial strength and very low growth.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Jazz Pharmaceuticals is pricier than similar companies

Jazz Pharmaceuticals's P/E (trailing 12 months): 71.5, +185% against the median of a group of 7 similar companies (25.1).

Compared with 7 similar companies

Jazz Pharmaceuticals's metrics compared with similar companies
MetricJazz PharmaceuticalsPosition in the groupBand
P/E (trailing 12 months)71.5High
Forward P/E9.04Low
Operating margin27.4%Middle
ROE5.1%Middle
Debt/equity1.35High

Grey band: the middle half of the group; tick: the median; dot: Jazz Pharmaceuticals. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.21B

Latest quarter · Q2 2026

Net income

$192.8M

Latest quarter · Q2 2026

Quarterly net margin

16.0%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$15.5B
P/E
71.5
EPS
$3.38
Volume
496.7K
Daily trading
€162.36M
Dividend yield
0.00%

How Jazz Pharmaceuticals is changing

All results
  • Revenue grew 12.5% a year on average over the last 5 years

  • Operating margin fell from −1.8% to −10.1%

  • Shares outstanding up 7.9% in 5 years

Returns

Jazz Pharmaceuticals returns

$1,000 invested in Jazz Pharmaceuticals 5 years ago, on November 15, 2021, would be worth $1,736 today: +73.55% in total, +11.67% per year. This is the price return only: dividends are excluded.

PeriodJazz PharmaceuticalsS&P 500$1,000 becomes
1 month+14.81%−3.12%$1,148
6 months+3.97%+1.58%$1,040
Year to date+42.09%+10.46%$1,421
1 year+70.45%+12.23%$1,705
3 years+97.99%+71.41%$1,980
5 years+73.55%+61.48%$1,736
10 years+114.03%+249.40%$2,140

Over the last 6 months it has done better than 30% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Jazz Pharmaceuticals: technical analysis

Jazz Pharmaceuticals is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 7.7% below its all-time closing high ($261.62, August 4, 2026).

Trend
Upward
RSI (14 sessions)
61
Between 30 and 70
vs 200-session average
+9.78%

Support and resistance

Price areas where Jazz Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$265.71+10.00%2 touches, last on August 25, 2026
  2. Last price$241.55
  3. Support$241.20−0.14%4 touches, last on October 5, 2026
  4. Support$234.73−2.82%2 touches, last on September 9, 2026
  5. Support$222.49−7.89%2 touches, last on June 18, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.59
Volatility (60 sessions, annualised)
33.9%
Largest fall in the last year
−21.62%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Jazz Pharmaceuticals: seasonality

Average monthly price change over 20 years

+1.6%Jan+0.9%Feb+1.6%Mar−0.8%Apr+2.6%May+15.5%Jun+5.5%Jul+2.2%Aug−2.3%Sep−3.1%Oct+6.6%Nov+2.5%Dec

Over the last 20 years, the strongest month for Jazz Pharmaceuticals has been June: +15.51% on average, positive in 11 years out of 19. The weakest has been October: −3.13% on average, positive in 7 years out of 20. November, the current month, has been positive in 12 years out of 19 (+6.56% on average).

Show chart data
MonthAverageMedianPositive years
January+1.56%+1.56%11 of 19
February+0.91%+0.44%11 of 19
March+1.61%+1.59%11 of 19
April−0.79%+0.19%11 of 19
May+2.64%−3.25%9 of 19
June+15.51%+1.41%11 of 19
July+5.54%+4.12%13 of 20
August+2.22%+1.00%10 of 20
September−2.27%−1.77%6 of 20
October−3.13%−1.60%7 of 20
November+6.56%+4.89%12 of 19
December+2.47%+1.28%10 of 19

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Jazz Pharmaceuticals and its competitors

Sales are concentrated in the United States, which generated 89.8% of revenue, while Europe contributed 8.0% and other countries 2.2%. The company identifies, develops and commercializes pharmaceutical products, with Xywav treating narcolepsy and idiopathic hypersomnia, Epidiolex treating seizures linked to rare epilepsy syndromes, and Rylaze and Enrylaze treating acute lymphoblastic leukemia. Its oncology range also includes Zepzelca for small cell lung cancer, Ziihera for biliary tract cancers and Modeyso for diffuse midline glioma.

Headquarters
Dublin, Ireland
Employees
2,890
Founded
2003
Chief executive
Renee Gala
Jazz Pharmaceuticals and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Jazz PharmaceuticalsJAZZ$15.5B27.4%71.5+3.97%
BridgeBio PharmaBBIO$15.25B-37.3%—+14.12%
ExelixisEXEL$16.84B40.2%20.7+34.53%
Ascendis PharmaASND$18.06B30.9%18.1+13.06%
Bio-TechneTECH$11.44B21.7%66.8+62.17%
Halozyme TherapeuticsHALO$11.43B56.7%25.1+43.18%

Same industry or related industries, similar size. Compare Jazz Pharmaceuticals with its competitors · Full profile